Iwase Madoka, Tsunoda Hiroko, Nakayama Kanako, Morishita Emiko, Hayashi Naoki, Suzuki Koyu, Yamauchi Hideko
Department of Breast Surgical Oncology, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
Department of Radiology, St. Luke's International Hospital, Tokyo, Japan.
Breast Cancer. 2017 Jul;24(4):579-584. doi: 10.1007/s12282-016-0742-z. Epub 2016 Nov 21.
Because of the increasing availability of screening mammography and spread of information about its benefits, the incidence of early breast cancer has been increasing in Japan. However, screening mammography can result in overdiagnoses or false positives, causing in some subjects undergoing unnecessary invasive procedures. The current mammography guidelines recommend further investigation of subjects with grouped amorphous calcifications; this recommendation may have resulted in overdiagnoses or false positives.
We retrospectively reviewed the charts of patients who had undergone screening mammography in the screening unit of our institution from January 2011 to December 2012 and been found to have grouped amorphous calcifications. Of the 233 such cases, 17 had been lost to follow-up, whereas whether the lesions were actually benign or malignant had been determined in the remaining 216 (92.7%).
Six (2.8%) of 216 subjects with grouped amorphous calcifications were diagnosed as having malignancy and the remaining 210 (97.2%) as having benign lesions. Four of the six cases (1.9%) with malignancy had ductal carcinoma in situ and two (0.9%) 3 and 4 mm diameter invasive cancers of luminal type and nuclear grade 1.
Grouped amorphous calcifications identified on screening mammography contribute minimally to detection of breast cancer and are not thought to be associated with any identifiable improvement in prognosis; present recommendations concerning this finding may result in false positives and overdiagnoses.
由于乳腺钼靶筛查的普及以及其益处的信息传播,日本早期乳腺癌的发病率一直在上升。然而,乳腺钼靶筛查可能导致过度诊断或假阳性,使一些受试者接受不必要的侵入性检查。当前的乳腺钼靶指南建议对伴有成簇不定形钙化的受试者进行进一步检查;这一建议可能导致了过度诊断或假阳性。
我们回顾性分析了2011年1月至2012年12月在本机构筛查单元接受乳腺钼靶筛查且发现有成簇不定形钙化的患者病历。在这233例病例中,17例失访,其余216例(92.7%)的病变最终确定为良性或恶性。
216例有成簇不定形钙化的受试者中,6例(2.8%)被诊断为恶性肿瘤,其余210例(97.2%)为良性病变。6例恶性病例中有4例(1.9%)为导管原位癌,2例(0.9%)为直径3和4毫米的管腔型1级核分级浸润性癌。
乳腺钼靶筛查中发现的成簇不定形钙化对乳腺癌检测的贡献极小,且认为与预后的任何可识别改善无关;关于这一发现的当前建议可能导致假阳性和过度诊断。